Developer docs
API playgroundTry for free, no card

Search company profiles

DaltonTx

Full company profile

uuid00008zw

Namestring
DaltonTx
Legal namestring
DaltonTx Limited
Websiteurl
daltontx.com
Company typeenum
Private
Founded yearint
2025
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, computational chemistry, machine learning platform, biologics discovery, pharmaceutical AI
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Platform Subscription/ Licensing
TypeSubscription Recurring
Description

Enterprise licensing of the Dalton platform to pharma, biotech, and CROs for AI-enabled drug discovery capabilities. The platform is offered as infrastructure that organisations can integrate into their existing workflows, suggesting a subscription or licensing model.

pharmaphorum.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

DaltonTx offers the Dalton platform, an AI-powered drug discovery system that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. The platform covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. It links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory across programmes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Retrospective evaluation shows potential for more efficient candidate selection and reduced synthesis burden on legacy oncology programme
Product overview1 text field

DaltonTx offers a single unified product platform called Dalton — an AI-enabled drug discovery platform that integrates agentic AI, human expertise, and experimental data into a continuous learning engine. The platform is purpose-built for both small molecules and biologics, covering the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. The platform links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory over time, helping teams understand what worked, what failed, and why. Scientists interact with the system through conversational workflows, combining their expertise with an engine that iterates and learns.

Product and service1 record
1Dalton platform
CategoryAI drug discovery platform
Description

AI-powered drug discovery platform that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. Covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation, and is offered to pharma, biotech, and CRO customers as enterprise-integrated infrastructure.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Strategic collaboration with leading integrated drug discovery CRO. DaltonTx's platform incorporated into Sygnature Discovery's computational and medicinal chemistry toolkit alongside existing tools including SygDesign, BullFrog AI, and Iktos. Sygnature Discovery is conducting retrospective evaluation of a legacy oncology programme with a Phase I clinical candidate to assess platform's impact on candidate selection efficiency.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Collaboration to advance precision delivery systems for oligotherapeutic medicines, initially focusing on CNS delivery. Combines Bonito's giga-scale encoded ligand libraries and functional cellular selection platform with DaltonTx's adaptive AI for iterative modelling, prediction, and optimization of delivery ligands. Companies aim to establish iterative learning loop for discovering delivery systems for tissues historically inaccessible to oligotherapeutics.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Technology transfer and support organisation for University of Oxford, providing support to DaltonTx as the company was founded on technology developed at Oxford.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Generative AI platform for small molecule drug discovery. Coexists with DaltonTx in Sygnature Discovery's toolkit, making it a directly comparable competitor for AI-enabled medicinal chemistry workflows.

TypeBroad incumbent
Description

Cloud-based R&D platform serving biotech customers with lab informatics, molecular biology, and registry capabilities. Comparable in serving biotech R&D teams but at a much broader, infrastructure-level layer rather than AI discovery.

TypeDirect peer
Description

Physics-based computational chemistry and AI platform for molecular design. A direct competitor in enterprise pharma AI drug discovery, with a longer commercial track record and larger installed base.

TypeDirect peer
Description

AI-driven drug discovery platform focused on improving clinical trial success rates through proprietary data networks. Another complementary platform at Sygnature Discovery alongside Dalton, with overlapping customer base in AI-enabled discovery.

5Antiverse
TypeEmerging player
Description

AI-driven antibody discovery platform using generative models. Comparable as a UK-headquartered, early-stage AI biologics discovery peer with overlapping biotech customer base, particularly for novel antibody and biologics programmes.

TypeDirect peer
Description

AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Competes directly with DaltonTx in pharma-facing AI discovery platforms, though with a much larger funding base and proprietary pipeline.

TypeDirect peer
Description

End-to-end AI-driven small molecule drug discovery company. DaltonTx's CEO, CTO, and CSO all previously built pioneering AI platforms at Exscientia, making it the most direct comparable in technology approach, customer base (pharma), and platform model.

TypeEmerging player
Description

AI platform for protein and biologics design. Comparable to DaltonTx's biologics discovery capability and overlapping customer base in biotech pursuing novel biologics, though with narrower modality focus.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable in platform approach and pharma customer base, though focused on phenotypic screening and pooled-data model architecture.

10Isomorphic Labs
TypeEmerging player
Description

Alphabet-backed AI drug discovery company focused on applying DeepMind's AlphaFold-derived approaches. Comparable in long-term ambition to build AI foundations of pharma R&D, though backed by vastly greater resources and not yet at full commercial scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DaltonTx

AI Drug Discovery Platformdaltontx.com

DaltonTx firmographics

Firmographics
Name
DaltonTx
Legal name
DaltonTx Limited
Website
https://daltontx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

DaltonTx industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Software Publishers (5132)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Computational chemistry
  • Machine learning platform
  • Biologics discovery
  • Pharmaceutical AI

Where DaltonTx is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

DaltonTx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Platform Subscription/ Licensing: Enterprise licensing of the Dalton platform to pharma, biotech, and CROs for AI-enabled drug discovery capabilities. The platform is offered as infrastructure that organisations can integrate into their existing workflows, suggesting a subscription or licensing model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

DaltonTx product offering

Product offering

Core offering

DaltonTx offers the Dalton platform, an AI-powered drug discovery system that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. The platform covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. It links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory across programmes.

Product overview

DaltonTx offers a single unified product platform called Dalton — an AI-enabled drug discovery platform that integrates agentic AI, human expertise, and experimental data into a continuous learning engine. The platform is purpose-built for both small molecules and biologics, covering the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. The platform links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory over time, helping teams understand what worked, what failed, and why. Scientists interact with the system through conversational workflows, combining their expertise with an engine that iterates and learns.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dalton platform AI-powered drug discovery platform that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. Covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation, and is offered to pharma, biotech, and CRO customers as enterprise-integrated infrastructure.

Quantifiable outcome

  • Retrospective evaluation shows potential for more efficient candidate selection and reduced synthesis burden on legacy oncology programme

Companies that use DaltonTx

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

DaltonTx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature5 records

DaltonTx partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Sygnature DiscoverycoreStrategic or Co-development Partner · 4 June 2026Strategic collaboration with leading integrated drug discovery CRO. DaltonTx's platform incorporated into Sygnature Discovery's computational and medicinal chemistry toolkit alongside existing tools including SygDesign, BullFrog AI, and Iktos. Sygnature Discovery is conducting retrospective evaluation of a legacy oncology programme with a Phase I clinical candidate to assess platform's impact on candidate selection efficiency.
  • Bonito BiosciencescoreStrategic or Co-development Partner · 27 May 2026Collaboration to advance precision delivery systems for oligotherapeutic medicines, initially focusing on CNS delivery. Combines Bonito's giga-scale encoded ligand libraries and functional cellular selection platform with DaltonTx's adaptive AI for iterative modelling, prediction, and optimization of delivery ligands. Companies aim to establish iterative learning loop for discovering delivery systems for tissues historically inaccessible to oligotherapeutics.
  • Oxford University InnovationminorStrategic or Co-development Partner · 23 September 2025Technology transfer and support organisation for University of Oxford, providing support to DaltonTx as the company was founded on technology developed at Oxford.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

DaltonTx competitors and assessment

Company assessment

Direct peers

  • Iktos: Generative AI platform for small molecule drug discovery. Coexists with DaltonTx in Sygnature Discovery's toolkit, making it a directly comparable competitor for AI-enabled medicinal chemistry workflows.
  • Schrödinger: Physics-based computational chemistry and AI platform for molecular design. A direct competitor in enterprise pharma AI drug discovery, with a longer commercial track record and larger installed base.
  • BullFrog AI: AI-driven drug discovery platform focused on improving clinical trial success rates through proprietary data networks. Another complementary platform at Sygnature Discovery alongside Dalton, with overlapping customer base in AI-enabled discovery.
  • Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Competes directly with DaltonTx in pharma-facing AI discovery platforms, though with a much larger funding base and proprietary pipeline.
  • Exscientia: End-to-end AI-driven small molecule drug discovery company. DaltonTx's CEO, CTO, and CSO all previously built pioneering AI platforms at Exscientia, making it the most direct comparable in technology approach, customer base (pharma), and platform model.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Directly comparable in platform approach and pharma customer base, though focused on phenotypic screening and pooled-data model architecture.

Broad incumbents

  • Benchling: Cloud-based R&D platform serving biotech customers with lab informatics, molecular biology, and registry capabilities. Comparable in serving biotech R&D teams but at a much broader, infrastructure-level layer rather than AI discovery.

Emerging players

  • Antiverse: AI-driven antibody discovery platform using generative models. Comparable as a UK-headquartered, early-stage AI biologics discovery peer with overlapping biotech customer base, particularly for novel antibody and biologics programmes.
  • Cradle Bio: AI platform for protein and biologics design. Comparable to DaltonTx's biologics discovery capability and overlapping customer base in biotech pursuing novel biologics, though with narrower modality focus.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company focused on applying DeepMind's AlphaFold-derived approaches. Comparable in long-term ambition to build AI foundations of pharma R&D, though backed by vastly greater resources and not yet at full commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

DaltonTx social profiles

Digital presence

DaltonTx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DaltonTx leadership team

Management profile

Number of profiles

Profiles4 records

DaltonTx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DaltonTx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DaltonTx

What does DaltonTx do?

DaltonTx offers the Dalton platform, an AI-powered drug discovery system that integrates agentic AI, human expertise, and experimental data into a continuous learning engine for small molecules and biologics. The platform covers the full discovery lifecycle including data ingestion, model training, molecule generation, synthesis planning, and experiment prioritisation. It links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system that captures organisational memory across programmes.

Is DaltonTx a public or private company?

DaltonTx is a private company. It is classified as venture growth investor backed and is currently operating.

When was DaltonTx founded?

DaltonTx was founded in 2025. It employs 11 to 50 people.

Where is DaltonTx based?

DaltonTx is headquartered in London, United Kingdom, in the Europe region.

How does DaltonTx make money?

One revenue line is on record: platform Subscription/ Licensing.

Who are DaltonTx's main competitors?

Direct peers on record are Iktos, Schrödinger, BullFrog AI, Insilico Medicine, Exscientia and Recursion Pharmaceuticals. Benchling is listed as a broad incumbent. Emerging players are Antiverse, Cradle Bio and Isomorphic Labs.

Does DaltonTx have an API?

No public API is recorded for DaltonTx.

What industry is DaltonTx in?

DaltonTx's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialDaltontx Appoints Melissa Landon As Chief Commercial Officer To Drive Commercial Growth And Strategic PartnershipsDaltonTx appointed Melissa Landon as Chief Commercial Officer to lead commercial strategy. She brings 20+ years of AI/ML experience in drug discovery, including roles at Merck and Cyclica. The appointment follows external validation of Dalton's platform with partners like Sygnature and Bonito Biosciences.GlobeNewswireDaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnershipsDaltonTx appointed Melissa Landon as Chief Commercial Officer to lead commercial strategy. She brings 20+ years of AI/ML experience in drug discovery, including roles at Merck and Cyclica. The appointment follows external validation of Dalton's platform with partners like Sygnature and Bonito Biosciences.The future of tradingDaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnershipsDaltonTx appointed Melissa Landon as Chief Commercial Officer to lead its commercial strategy. She brings 20+ years of AI/ML experience in drug discovery, including roles at Merck and Cyclica. The appointment follows external validation of its Dalton platform with partners like Sygnature and Bonito Biosciences.GlobeNewswireDaltonTx awarded grant to accelerate AI-powered tuberculosis drug discoveryDaltonTx received a Gates Foundation grant to accelerate tuberculosis drug discovery using its AI platform. The project will screen hundreds of essential TB proteins and partner with Ersilia to make tools accessible in low-resource settings.pharmaphorumMeet Dalton, a new AI-powered drug discovery platformUK start-up DaltonTx has launched its AI-powered drug discovery platform called Dalton, designed to handle the full drug discovery process from raw data and model training through molecular design, synthesis, and decision-making. The London-based company, whose founders include former scientists from AstraZeneca, Exscientia, and the University of Oxford, has signed up contract research organisation Sygnature Discovery and oligotherapeutic drug developer Bonito Biosciences as its first two clients. DaltonTx differentiates itself from rivals including Recursion Pharma, Insilico Medicine, Schrödinger, NVIDIA, and Alphabet/Isomorphic Labs by offering an enablement-focused model with strict data privacy protections that keep client data and models separate.IndianpharmapostSygnature Discovery partners with DaltonTx to enhance AI-driven drug discovery capabilitiesSygnature Discovery, a leading integrated drug discovery contract research organisation, has entered into a strategic collaboration with DaltonTx to strengthen its AI-enabled drug discovery capabilities and accelerate medicinal chemistry decision-making. Under the partnership, DaltonTx's platform will be incorporated into Sygnature Discovery's existing computational and medicinal chemistry toolkit alongside proprietary and third-party technologies including SygDesign, BullFrog AI, and Iktos. As part of the collaboration, Sygnature Discovery is conducting a retrospective evaluation of a legacy oncology programme involving a small-molecule clinical candidate currently in Phase I development to assess whether the Dalton platform could have enabled more efficient candidate selection.The Manila TimesDaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaborationDaltonTx launched Dalton, a drug discovery platform integrating agentic AI, human expertise, and experimental data into a continuous learning engine designed to help teams learn faster from every decision across the design-make-test-analyse cycle. The company simultaneously announced a collaboration with Sygnature Discovery, a leading integrated drug discovery CRO, to use the platform alongside existing tools including SygDesign, BullFrog AI, and Iktos to strengthen AI-enabled drug discovery capabilities and accelerate medicinal chemistry decision-making. Sygnature Discovery is conducting a retrospective evaluation using a legacy oncology programme with a small molecule clinical candidate in Phase I development to assess whether the platform could have enabled more efficient candidate selection.Let's Data ScienceDaltonTx launches Dalton platform, partners with SygnatureDaltonTx launched a new drug discovery platform called Dalton, which links molecules, assays, models, and experimental outcomes into a single learning system. The company announced a collaboration with Sygnature Discovery to use the platform for enhancing AI-enabled drug discovery workflows.GlobeNewswireDaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaborationDaltonTx announced the launch of Dalton, its AI-powered drug discovery platform that integrates AI agents, human expertise, and experimental data into a continuous learning system for small molecules and biologics. The company simultaneously announced a collaboration with Sygnature Discovery, a leading integrated drug discovery CRO, which will use the Dalton platform to enhance its AI-enabled capabilities and accelerate medicinal chemistry decision-making. Sygnature Discovery is conducting a retrospective evaluation using a legacy oncology programme with a small molecule candidate in Phase I development to assess whether the platform could have improved decision-making efficiency and reduced synthesis burden.GenengnewsBonito Biosciences and DaltonTx Collaborate on Precision Delivery for OligotherapeuticsBonito Biosciences and DaltonTx agreed to collaborate on precision delivery systems for oligotherapeutics, focusing initially on central nervous system delivery. The partnership combines Bonito's functional delivery data engine with DaltonTx's AI systems to optimize delivery ligands. The companies aim to establish an iterative learning loop for rapid discovery of delivery systems.